Salvatore Privitera Sells 3,657 Shares of AtriCure (NASDAQ:ATRC) Stock

AtriCure, Inc. (NASDAQ:ATRC) insider Salvatore Privitera sold 3,657 shares of AtriCure stock in a transaction that occurred on Tuesday, September 8th. The shares were sold at an average price of $55.00, for a total transaction of $201,135.00. Following the sale, the insider owned 147,264 shares of the company’s stock, valued at approximately $8,099,520. The trade was a 2.42% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Salvatore Privitera also recently made the following trade(s):

• On Wednesday, September 2nd, Salvatore Privitera sold 7,763 shares of AtriCure stock. The stock was sold at an average price of $52.50, for a total transaction of $407,557.50.

AtriCure Stock Performance

AtriCure stock opened at $54.54 on Friday. The firm’s fifty day moving average price is $42.41 and its 200-day moving average price is $33.55. The company has a debt-to-equity ratio of 0.14, a quick ratio of 3.19 and a current ratio of 4.22. The stock has a market cap of $2.77 billion, a P/E ratio of 259.73 and a beta of 1.26. AtriCure, Inc. has a fifty-two week low of $25.36 and a fifty-two week high of $55.72.

AtriCure (NASDAQ:ATRC) last released its earnings results on Thursday, July 23rd. The medical device company reported $0.18 EPS for the quarter. AtriCure had a return on equity of 2.34% and a net margin of 1.85%.The business had revenue of $153.60 million for the quarter, compared to analysts’ expectations of $151.80 million. During the same quarter in the prior year, the firm earned ($0.13) earnings per share. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. On average, equities research analysts expect that AtriCure, Inc. will post 0.29 earnings per share for the current fiscal year.

Institutional Investors Weigh In On AtriCure

Several hedge funds have recently added to or reduced their stakes in ATRC. Tidal Investments LLC boosted its position in shares of AtriCure by 46.2% during the second quarter. Tidal Investments LLC now owns 19,091 shares of the medical device company’s stock valued at $534,000 after buying an additional 6,034 shares during the last quarter. WINTON GROUP Ltd purchased a new stake in shares of AtriCure during the 2nd quarter valued at about $1,002,000. Engineers Gate Manager LP grew its stake in shares of AtriCure by 12.3% in the second quarter. Engineers Gate Manager LP now owns 48,160 shares of the medical device company’s stock worth $1,348,000 after acquiring an additional 5,283 shares during the period. Integrated Wealth Concepts LLC bought a new position in AtriCure during the second quarter valued at approximately $46,000. Finally, Allworth Financial LP lifted its position in AtriCure by 372.8% during the second quarter. Allworth Financial LP now owns 1,527 shares of the medical device company’s stock valued at $43,000 after purchasing an additional 1,204 shares during the period. 99.11% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the stock. Piper Sandler increased their price target on shares of AtriCure from $50.00 to $60.00 and gave the company an “overweight” rating in a research report on Thursday, August 27th. UBS Group lowered their price objective on shares of AtriCure from $55.00 to $50.00 and set a “buy” rating for the company in a research note on Tuesday, July 28th. Citigroup reiterated a “market outperform” rating on shares of AtriCure in a report on Tuesday, July 21st. Weiss Ratings upgraded AtriCure from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, August 19th. Finally, Raymond James Financial set a $52.00 price objective on AtriCure in a report on Tuesday, July 21st. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat, AtriCure presently has an average rating of “Moderate Buy” and a consensus target price of $52.00.

AtriCure Company Profile

AtriCure, Inc (NASDAQ: ATRC) is a medical device company focused on the treatment of atrial fibrillation (AF) and related conditions. The company develops, manufactures and sells surgical and minimally invasive technologies designed to restore normal heart rhythm and reduce the risk of stroke associated with AF.

Its product portfolio includes the AtriClip system for excluding the left atrial appendage, the Isolator and Synergy systems for surgical ablation, and the cryoICE system, which uses cryothermal energy in cardiac procedures.